Predictors of neuroleptic-induced dyskinesia and parkinsonism: The influence of measurement methods and definitions

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 560-565

  Dean, Charles E ^a,b   Kuskowski, Michael A ^a,b   Caligiuri, Michael P ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSKINESIA IDENTIFICATION SCALE CONDENSED USER VERSION; FEMALE; HEAD INJURY; HUMAN; INSTRUMENTAL MEASUREMENT; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MOOD DISORDER; MOTOR ACTIVITY; MOTOR DYSFUNCTION; PARKINSONISM; POLYPHARMACY; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SMOKING; TARDIVE DYSKINESIA;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGING; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CRANIOCEREBRAL TRAUMA; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE, SECONDARY; PREDICTIVE VALUE OF TESTS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 33751114417     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000245559.14284.e3     Document Type: Article

References (36)

1. Dean CE, Russell JM, Kuskowski MA, et al. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol. 2004;24:298-304.
2. Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenic patients. Am J Psychiatry. 2004;161:160-163.
3. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976.
4. Sprague RL, Kalachnik JE, Breuning SE, et al. The Dyskinesia Identification System-Coldwater (DIS-Co): a tardive dyskinesia rating scale for the developmentally disabled. Psychopharmacol Bull. 1984;20:328-338.
5. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl 44):11-19.
6. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
7. Ismail B, Cantor-Graae E, McNeil TF. Neurodevelopmental origins of tardivelike dyskinesia in schizophrenia patients and their siblings. Schizophr Bull. 2001;27:629-642.
8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res. 1975;12:189-198.
9. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9:97-113.
10. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756-765.
11. Pies RW. Must we now consider SRIs neuroleptics. [Editorial]. J Clin Psychopharmacol. 1997;17:443-445.
12. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692-698.
13. Caligiuri MP, Jeste DV. Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacology (Berl). 2004;176:281-286.
14. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27:561-568.
15. 2 imbalance. In: Yassa R, Vasavan Nair NP, Jeste DV, eds. Neuroleptic-induced Movement Disorders. Cambridge, UK: Cambridge University Press; 1997:141-160.
16. Bai J, Fang H, Novikova SI, et al. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry. 2004;56:427-440.
17. Craig AM, Boudin H. Molecular heterogeneity of central synapes: afferent and target regulation. Nat Neurosci. 2001;4:569-578.
18. Steiner H, Kitai ST. Unilateral dopamine depletion: time-dependent effects on cortical function and behavioural correlates. Eur J Neurosci. 2001;14:1390-1404.
19. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133-139.
20. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among chronic outpatients maintained on neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723-733.
21. Waddington JL, O'Callaghan E, Buckley P, et al. Vulnerability to tardive dyskinesia: an exploration of individual patient factors. In: Yassa R, Vasavan Nair NP, Jeste DV, eds. Neuroleptic-induced Movement Disorders. Cambridge, UK: Cambridge University Press; 1997:56-58.
22. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. [letter]. Arch Gen Psychiatry. 1982;39:486-487.
23. Caligiuri MP, Lohr JB, Bracha HS, et al. Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry. 1991;29:139-148.
24. Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987;6:511-521.
25. Lauterbach EC, Carter WG, Rathke KM, et al. Tardive dyskinesia-diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service. Schizophr Bull. 2001;27:601-614.
26. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol. 1999;19:203-208.
27. Hansen TH, Weigel RM, Brown WL, et al. A longitudinal study of correlations among tardive dyskinesia, drug-induced parkinsonism, and psychosis. J Neurol Neurosurg Psychiatry. 1992;4:29-35.
28. Brown KW, White T. The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry. 1991;30:1182-1190.
29. Levy E, Margolese HC, Annable L, et al. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes healthcare guidelines to antipsychotic use. Can J Psychiatry. 2004;49:398-402.
30. Ganzini L, Casey DE, Hoffman WF, et al. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull. 1992;28:281-286.
31. Byne W, Stamu C, White L, et al. Prevalence and correlates of parkinsonism in an institutionalized population of patients with schizophrenia. Int J Geriatr Psychiatry. 2000;15:7-13.
32. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry. 1999;56:836-841.
33. Lohr JB, Caligiuri MP, Edson R, et al. Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394. J Clin Psychopharmacol. 2002;22:196-200.
34. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. 2004;38:445-449.
35. Lencer R, Eismann G, Kasten M, et al. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry. 2004;185:465-471.
36. Waddington JL, Youseff HA, Kinella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10 year period. Br J Psychiatry. 1998;173:325-329.